美国准备批准首款镰状细胞病患者的基因编辑疗法

#美国准备批准首款镰状细胞病患者的基因编辑疗法#【美国准备批准首款镰状细胞病患者的基因编辑疗法】据报道，美国食品和药物管理局预计将批准exa-cel基因编辑用于治疗镰状细胞性贫血病患者。Exa-cel将成为美国首款使用CRISPR基因编辑技术的获批药物。这种治疗方法由Vertex Pharmaceuticals和CRISPR Therapeutics共同开发。预计每位患者的费用约为200万美元。https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/usstock/c/2023-12-07/doc-imzxfekq1292844.shtml","multimedia":{"img_url":["https://n.sinaimg.cn/zhibo/50/w2000h1250/20231207/38c7-d48fb79f4fb987c1c993339c8580a3ac.jpg"]},"commentid":"live:finance-152-3399748:0","compere_id":0,"creator":"zhangjun@staff.sina.com.cn","mender":"zhangjun@staff.sina.com.cn","create_time":"2023-12-07 22:44:47","update_time":"2023-12-07 22:44:47","is_need_check":"0","check_time":"1970-01-01 08:00:01","check_status":"1","check_user":"","is_delete":0,"top_value":0,"is_focus":0,"source_content_id":"0","anchor_image_url":"","anchor":"直播员","ext":"{"stocks":[],"needPush":false,"needAIPush":false,"needCMSLink":true,"needCalender":false,"needProvince":"0"}","old_live_cid":"0","tab":"","is_repeat":"0","tag":[{"id":"2","name":"行业"},{"id":"3","name":"公司"},{"id":"4","name":"数据"},{"id":"5","name":"市场"},{"id":"6","name":"观点"}],"like_nums":0,"comment_list":{"list":[],"total":0,"thread_show":0,"qreply":0,"qreply_show":0,"show":0},"docurl":"","rich_text_nick_to_url":[],"rich_text_nick_to_routeUri":[],"compere_info":""},{"id":3399747,"zhibo_id":152,"type":0,"rich_text":"德国财长Lindner：德国愿意针对欧盟财政制度找到共识。德国和法国围绕欧盟财政问题中90%的主要议题存在共识。